GLP-1 Receptor Agonist Market Summary

The global GLP-1 receptor agonist market size was estimated at USD 53.46 billion in 2024 and is projected to reach USD 156.71 billion by 2030, growing at a CAGR of 17.46% from 2025 to 2030. This strong growth trajectory is primarily driven by the introduction of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a robust product pipeline targeting both diabetes and obesity applications, and the high clinical efficacy of these drugs in managing blood glucose levels and associated cardiometabolic conditions. Increasing awareness of obesity-related complications and type 2 diabetes is further driving the adoption of GLP-1 receptor agonists globally.

In May 2024, Innovent Biologics announced that its type 2 diabetes candidate, mazdutide, outperformed Eli Lilly’s Trulicity (dulaglutide) in a Phase III clinical trial. The study demonstrated that mazdutide provided superior glycemic control and offered multiple cardiometabolic benefits, including significant weight reduction, improved blood lipid profiles, normalized liver enzyme levels, reduced serum uric acid, and better regulation of blood pressure. Such advancements highlight the potential of new GLP-1 receptor agonist therapies to enhance patient outcomes and expand market growth opportunities.

Key Market Trends & Insights

• Regional Market Share: North America dominated the GLP-1 receptor agonist market, accounting for 77.72% of the total revenue share in 2024.
• Country-Level Insight: Within North America, the United States held the largest market share, reflecting strong healthcare infrastructure and high adoption of innovative therapies.
• Product Segment: The ozempic segment led the market in 2024, accounting for 34.17% of the revenue, driven by its established efficacy and strong brand recognition.
• Distribution Channel: The hospital pharmacies segment accounted for the largest revenue share of 55.09% in 2024, serving as a primary channel for GLP-1 receptor agonist distribution.
• Application Segment: Type 2 diabetes mellitus dominated the market in 2024 and is expected to continue growing at a CAGR of 17.06% over the forecast period, reflecting the high prevalence of the condition and increased treatment demand.
• Route of Administration: The parenteral segment held the largest revenue share in 2024 and is projected to grow at a CAGR of 17.42% from 2025 to 2030, indicating continued preference for injectable GLP-1 receptor agonists among patients and healthcare providers.

Order a free sample PDF of the GLP-1 Receptor Agonist Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 53.46 Billion
• 2030 Projected Market Size: USD 156.71 Billion
• CAGR (2025-2030): 17.46%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Some leading players operating in the market include AstraZeneca, Sanofi, Novo Nordisk A/S, and Eli Lilly and Company. Key players use existing customer bases in the region to prioritize maintaining high-quality standards and gain high market size access. This strategy is useful for brands that have already built market positions. These players are heavily investing in infrastructure, allowing them to process & analyze a large volume of samples efficiently. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their presence.

Hanmi Pharm. Co., Ltd, Eccogen, and D&D Pharmatech are some emerging players in the market. These companies focus on achieving funding support from government bodies and healthcare organizations aided with novel launches to capitalize on untapped avenues.

Key Players

• Eli Lilly and Company
• Sanofi
• Novo Nordisk A/S
• AstraZeneca

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global GLP-1 receptor agonist market is set to experience substantial growth in the coming years, fueled by innovative therapies, strong clinical efficacy, and expanding applications in type 2 diabetes and obesity management. North America, led by the United States, remains the dominant market due to advanced healthcare infrastructure and high adoption of novel treatments. With leading products like ozempic and emerging candidates such as mazdutide offering enhanced therapeutic benefits, hospital pharmacies remain a key distribution channel. Parenteral administration continues to be the preferred route. Overall, the market is expected to witness continued innovation, improved patient outcomes, and robust revenue expansion.